Obagi Medical Products to Report Second Quarter 2008 Financial Results and Host a Conference Call on August 11

Investors interested in participating in the live call can dial (800) 762-8795 from the U.S. International callers can dial (480) 629-9029. A telephone replay will be available approximately two hours after the call concludes and will be available through Monday, August 25, by dialing (800) 406-7325 from the U.S., or (303) 590-3030 for international callers and entering confirmation code 3903043.

There also will be a simultaneous webcast available on the Investor Relations section of the Company's web site at www.obagi.com. For those unable to participate during the live broadcast, the webcast will be archived for 30 days.

About Obagi Medical Products, Inc.

Obagi Medical Products develops and commercializes skin health products for the dermatology, plastic surgery, and related aesthetic markets. Using its Penetrating Therapeutics(TM) technologies, its products are designed to improve penetration of agents across the skin barrier for common and visible skin conditions including chloasma, melasma, senile lentigines, acne vulgaris and sun damage. Obagi has introduced the following skin care products: Obagi Nu-Derm(R), 1988; Obagi-C(R) Rx (the first and only prescription-strength vitamin C and hydroquinone system), 2004; Obagi(R) Professional-C (a line of highly stable vitamin C serums), 2005; Obagi(R) Condition and Enhance for use with cosmetic procedures, 2006; Obagi ELASTIderm(TM) eye treatment and Obagi CLENZIderm(R) M.D. acne therapeutic systems, 2007; a formulation of Obagi CLENZIderm(R) M.D. Systems for normal to dry skin, June 2007; and Obagi ELASTIderm(TM) Decolletage System, January 2008. Visit www.obagi.com for more information.

SOURCE: Obagi Medical Products, Inc.

Company: Obagi Medical Products, Inc. Preston Romm CFO, EVP of Finance, Operations and Administration 562-628-1007 or Investors: ICR, Inc. Ina McGuinness/Lena Adams, 310-954-1100